Teva execs says Cephlon probe won't derail deal; AZ breast cancer drug gets Japanese OK;

@FiercePharma: Merck joins drug cos. looking outside pharma for expertise: New strategy chief from Lenovo Article | Follow @FiercePharma

> Bill Marth, Teva Pharmaceutical Industries' ($TEVA) North American chief, told the Philadelphia Inqurier that the company's planned merger with U.S.-based Cephalon ($CEPH) was still on track despite a newly disclosed federal investigation of that company. Report

> AstraZeneca ($AZN) said its estrogen-receptor agonist Faslodex won approval in Japan for treating postmenopausal women with hormone receptor-positive metastatic breast cancer. Release

> Japan's Santen Pharmaceutical agreed to buy the French eye-drug company Novagali Pharma ($NOVA) for up to 102 million euros ($139 million). Story

> Pfizer sued Teva Pharmaceutical Industries to block the generics maker's attempt to market a generic version of its erectile dysfunction drug in Russia. Item

> The Gates Foundation-led vaccine alliance, GAVI, plans to fund rotavirus vaccination programs in 15 more developing countries. Report

> AstraZeneca ($AZN) bought back 401,000 more shares for 2853 pence per share. More

> Sagent Pharmaceuticals launched its version of paclitaxel, the widely used cancer treatment, in the U.S. market. Piece

Biotech News

@FierceBiotech: Intercell seeks drug-patch partners after stock meltdown. Report | Follow @FierceBiotech

@RyanMFierce: @JohnCFierce it's like the top 10 pharma wants to date RNAi without telling anyone. Did someone say RNAi has cooties? | Follow @RyanMFierce

@MaureenFierce: Childhood vaccine funds agreed for more poor nations. Article | Follow @MaureenFierce

> Santen strikes $139M deal to snap up Novagali's eye treatments. Item

Medical Device News

@FierceMedDev: Shuren says guidance on de novo coming shortly. #AdvaMed2011 | Follow @FierceMedDev

> J&J unit to buy SterilMed. Article

> DJO, Exos ink distribution agreement. Item

> Sony buys Micronics to enter new field. Report

> SpineGuard scores $6.2M. More

Drug Delivery News

> 'Nano-swimmers' could carry drugs to tumors. News

> FDA clears Smiths Medical's wireless infusion pump. Story

> Pacira's long-acting pain drug advancing. Story

> U.K.'s Silence grabs RNAi delivery deal with Big Pharma. Report

> Intercell seeks drug-patch partners after stock meltdown. Item

> Roche trial buoys antibody-based delivery of cancer drugs. Piece

And Finally... Retired Supreme Court Justice John Paul Stevens sees a precedent supporting President Obama's healthcare law in a 2005 medical-marijuana decision. Report

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.